In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Siemens acquires Bayer Diagnostics, Creates Integrated Diagnostics Powerhouse

Executive Summary

Following upon its announcement in May that it would pay $1.86 billion for Diagnostics Products, to bring an immunodiagnostics business in-house, Siemens announced in June that it will acquire Bayer Diagnostics for approximately €4.2 billion or $5.26 billion. Siemens thus catapults itself to the number two spot in the immunodiagnostics segment of IVD, after Roche, and by its calculations, now plays a close third to Abbott Laboratories in the overall in vitro diagnostics market.

You may also be interested in...



Is Diagnostics the New Biotech...and Will Pharma Embrace It?

The early biotech industry thrived on a combination of hope and hype while diagnostics, which evolved using many of the same tools, was traditionally viewed -- and priced -- almost as a commodity. Now we're seeing the advent of complex, high-value diagnostics. As the techniques underlying tests increase in their biological complexity and the knowledge base of their developers about specific disease areas deepens, is the value proposition becoming more biotech-like?

Is Diagnostics the New Biotech...and Will Pharma Embrace It?

The early biotech industry thrived on a combination of hope and hype while diagnostics, which evolved using many of the same tools, was traditionally viewed -- and priced -- almost as a commodity. Now we're seeing the advent of complex, high-value diagnostics. As the techniques underlying tests increase in their biological complexity and the knowledge base of their developers about specific disease areas deepens, is the value proposition becoming more biotech-like?

The Digital Pathology Revolution: Breaking the Glass Ceiling

Among diagnostic specialties, anatomic pathology is the last holdout against the digital revolution. Pathologists still detect disease by looking at tissue samples on a glass slide through a microscope, just as they have done for a hundred years. But in the last couple of years, start-up companies have begun to break the bondage of pathologists to slides. Their solution: platforms for digitizing slides so they can be accessed through computer networks by clinicians anywhere in the world. Two start-ups, Aperio and BioImagene, have led the way and now all the big imaging manufacturers, the microscope companies and biomarker developers want in.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel